Cancer Treatment Reviews
Volume 37, Issue 3 , Pages 208-211 , May 2011

Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives

  • Lucia Del Mastro

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39 0105600666; fax: +39 0105600850.
    • ,
  • Alessia Levaggi

      Affiliations

    • Tel.: +39 0105600666; fax: +39 0105600850.
    • ,
  • Sara Giraudi

      Affiliations

    • Tel.: +39 0105600898; fax: +39 0105600850.
    • ,
  • Paolo Pronzato

      Affiliations

    • Tel.: +39 0105600668; fax: +39 0105600850.

Received 29 June 2010 ,Revised 23 July 2010 ,Accepted 23 July 2010.

References 

  1. Li CL, Daling JR, Malone KE, et al. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003;21:28–34
  2. Soreide JA, Varhaug JE, Fjosna HE, et al. Adjuvant endocrine treatment (goserelin vs tamoxifen) in premenopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur J Surg Oncol. 2002;28:505–510
  3. Mitsuyama S, Nomura Y, Ohno S, et al. Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan–Zoladex Breast Cancer Study Group Trial B (Japanese). Jpn J Cancer Chemother. 2005;32:2071–2077
  4. Hackshaw A, Baum M, Fornander T, et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009;101:341–349
  5. Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone–receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711–1723
  6. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. An overview of the randomized trials. Lancet 2005;365:1687–1717.
  7. Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92:903–911
  8. Davidson NE, O’Nell AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive steroid hormone receptor-positive breast cancer. Results from INT 0101 (E5188). J Clin Oncol. 2005;23:5973–5982
  9. Forward DP, Cheung KL, Jackson L, et al. Clinical and endocrine data for goserelin plus anastrozole as second line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer. 2004;90(3):590–594
  10. Rossi E, Morabito A, De Maio E, et al. Endocrine effects of adjuvant letrozole+triptorelin compared with tamoxifen+triptorelin in premenopausal patients with early breast cancer. J Clin Oncol. 2008;26(2):264–270
  11. Park IH, Ro J, Lee KS, et al. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol. 2010;28:2705–2711
  12. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zolendronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679–691
  13. International Bresat Cancer Study Group (IBCSG). Castiglione-Gertsch M, O’Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003;95(24):1833–46.
  14. Schmid P, Untch M, Kossè V, et al. Leuproline acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol. 2007;25:2509–2515
  15. Smith IE, Dowsett M, Yap YS, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhea: caution and suggested guidelines. J Clin Oncol. 2006;24:2444–2447
  16. National Cancer Institute Clinical Trials. <http://www.clinicaltrials.gov>. NCT00917969; NCT00066690; NCT00066703.
  17. Rivkees AS, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259:2123–2125
  18. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to preservation of embryo, oocytes, or ovaries. Oncologist. 2007;12(9):1044–1054
  19. Beck-Fruchter R, Weiss A, Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update. 2008;14(6):553–561
  20. Fox KR, Scialla J, Moore H. Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Oncol. 2003;22:13;[abstr 50]
  21. Recchia F, Sica G, De Filippis S, et al. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Dugs. 2002;13:417–424
  22. Urriticoechea A, Walsh G, Rigg A, et al. Ovarian function protection with goserelin during adjuvant chemotherapy in pre-menopausal women with early breast cancer. Breast Cancer Res Treat. 2004;88(Suppl. 1):S229;[abstr 6028]
  23. Del Mastro L, Catzeddu T, Boni L, et al. Prevention of chemotherapy induced menopause by temporary ovarian suppression with goserelin in young early breast cancer patients. Ann Oncol. 2006;17:74–78
  24. Badawy A, Elnashar A, El-Ashry M, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91(3):694–697
  25. Gerber B, Stehle H, Ricardo F, et al. ZORO: a prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). J Clin Oncol. 2009;27:526
  26. Leonard RC, Adamson D, Anderson R, et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol. 2010;28(Suppl.):15s;[abstr 590]
  27. Del Mastro L, Boni L, Michelotti A, et al. Role of luteinizing hormone-releasing hormone analog (LH-Rha) triptorelin in preserving ovarian function during chemotherapy for early breast cancer patients: results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol. 2010;28(Suppl.):15s;[abstr 528]

PII: S0305-7372(10)00134-9

doi: 10.1016/j.ctrv.2010.07.007

Cancer Treatment Reviews
Volume 37, Issue 3 , Pages 208-211 , May 2011

Article Tools